Xavier Pivot
#170,565
Most Influential Person Now
Researcher
Xavier Pivot's AcademicInfluence.com Rankings
Xavier Pivotcomputer-science Degrees
Computer Science
#10520
World Rank
#11053
Historical Rank
Computer Engineering
#152
World Rank
#154
Historical Rank
Data Science
#277
World Rank
#282
Historical Rank
Computational Linguistics
#2651
World Rank
#2678
Historical Rank
Download Badge
Computer Science
Why Is Xavier Pivot Influential?
(Suggest an Edit or Addition)According to Wikipedia, Xavier Pivot is a French oncologist, university professor, breast cancer specialist and general director of the Strasbourg Cancer Institute. He is best known for his research on treatments with trastuzumab in HER2-positive breast cancers.
Xavier Pivot's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- International network of cancer genome projects (2010) (1839)
- Landscape of somatic mutations in 560 breast cancer whole genome sequences (2016) (1574)
- Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. (2009) (982)
- MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. (2017) (950)
- Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. (2010) (855)
- Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. (2018) (580)
- The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2 (2019) (440)
- Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. (2007) (388)
- Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. (2007) (383)
- Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. (2013) (383)
- Patterns of somatic structural variation in human cancer genomes (2020) (377)
- Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. (2019) (354)
- Malnutrition is an independent factor associated with nosocomial infections. (2004) (330)
- 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. (2013) (319)
- Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2–Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study (2016) (305)
- Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. (2012) (246)
- Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. (2008) (227)
- AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. (2013) (222)
- CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. (2015) (202)
- Comprehensive molecular characterization of mitochondrial genomes in human cancers (2017) (197)
- Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer (2010) (193)
- Prognostic factors in primary breast sarcomas: a series of patients with long-term follow-up. (2003) (180)
- A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. (2008) (175)
- Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. (2013) (175)
- Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy. (2010) (155)
- Adjuvant chemotherapy for primary cardiac sarcomas: the IGR experience. (1998) (153)
- Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer (2013) (149)
- Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). (2003) (140)
- Role of STAT3 in CD4+CD25+FOXP3+ Regulatory Lymphocyte Generation: Implications in Graft-versus-Host Disease and Antitumor Immunity1 (2007) (130)
- Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study. (2014) (129)
- A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers (2016) (110)
- Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. (2010) (109)
- First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients. (2011) (108)
- Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer. (2004) (106)
- Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: results from AVADO. (2011) (98)
- Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study. (2015) (97)
- Phase III, randomized study of trastuzumab emtansine (T-DM1) {+/-} pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: Primary results from the MARIANNE study. (2015) (94)
- Novel role for STAT3 in transcriptional regulation of NK immune cell targeting receptor MICA on cancer cells. (2011) (92)
- Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis. (2013) (89)
- Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck (2001) (86)
- Impact of chemotherapy beyond the first line in patients with metastatic breast cancer (2007) (84)
- Analysis of Spontaneous Tumor-Specific CD4 T-cell Immunity in Lung Cancer Using Promiscuous HLA-DR Telomerase-Derived Epitopes: Potential Synergistic Effect with Chemotherapy Response (2012) (84)
- Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis. (1998) (82)
- 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial (2019) (82)
- Endpoints in cancer clinical trials. (2014) (79)
- Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer (2016) (79)
- Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy (2016) (73)
- Lapatinib combined with letrozole vs. letrozole alone for front line postmenopausal hormone receptor positive (HR+) metastatic breast cancer (MBC): first results from the EGF30008 Trial. (2009) (72)
- A Retrospective Study of First Indicators of Breast Cancer Recurrence (2000) (72)
- New advances in DPYD genotype and risk of severe toxicity under capecitabine (2017) (72)
- Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer. (2013) (70)
- Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes (2010) (69)
- A multifactorial approach including tumoural epidermal growth factor receptor, p53, thymidylate synthase and dihydropyrimidine dehydrogenase to predict treatment outcome in head and neck cancer patients receiving 5-fluorouracil (1999) (69)
- Prospective analysis of the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patients. (2011) (67)
- Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer. (2013) (66)
- Pharmacokinetics of platinum after oral or intravenous cisplatin: a phase 1 study in 32 adult patients (2004) (65)
- Discordance in early breast cancer for tumour grade, estrogen receptor, progesteron receptors and human epidermal receptor-2 status between core needle biopsy and surgical excisional primary tumour. (2011) (65)
- Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer. (2018) (64)
- Computerized physician order entry of injectable antineoplastic drugs: An epidemiologic study of prescribing medication errors (2010) (63)
- Lack of adaptation to severe malnutrition in elderly patients. (2002) (62)
- Concomitant twice‐a‐day radiotherapy and chemotherapy in unresectable head and neck cancer patients: A long‐term quality of life analysis (2001) (62)
- Dendritic cell and natural killer cell cross-talk: a pivotal role of CX3CL1 in NK cytoskeleton organization and activation. (2008) (61)
- HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-up. (2016) (61)
- The relationship of epidermal growth factor receptor levels to the prognosis of unresectable pharyngeal cancer patients treated by chemo-radiotherapy. (2001) (61)
- The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab. (2008) (61)
- A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results. (2018) (60)
- A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2‐positive early breast cancer (2016) (59)
- A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study. (2011) (59)
- Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III study. (2015) (58)
- Is routine triple endoscopy for head and neck carcinoma patients necessary in light of a negative chest computed tomography scan? (2004) (58)
- Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review (2014) (53)
- Added value of molecular targeted agents in oncology. (2011) (53)
- A limited sampling strategy for determining carboplatin AUC and monitoring drug dosage. (2000) (52)
- Natural killer cells prevent CD28-mediated Foxp3 transcription in CD4+CD25- T lymphocytes. (2007) (51)
- Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2–positive advanced breast cancer: Final results from MARIANNE (2019) (50)
- Prognostic impact of the epidermal growth factor receptor levels for patients with larynx and hypopharynx cancer. (2005) (49)
- A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: an analysis of the ATHENA trial. (2014) (48)
- Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer: Final Analysis of the HannaH Phase 3 Randomized Clinical Trial (2019) (48)
- Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy? (2007) (47)
- A unified definition of clinical anthracycline resistance breast cancer (2000) (46)
- Serum and intraperitoneal pharmacokinetics of cisplatin within intraoperative intraperitoneal chemotherapy: influence of protein binding (2005) (45)
- Prospective Clinical Utility Study of the Use of the 21-Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor-Positive Early Invasive Breast Cancer: Results From the SWITCH Study. (2015) (45)
- S4-8: First results of AVEREL, a randomized phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H) + docetaxel (DOC) as first-line therapy for HER2−positive locally recurrent/metastatic breast cancer (LR/mBC) (2011) (44)
- Phase I and pharmacokinetic study of the association of capecitabine-cisplatin in head and neck cancer patients. (2003) (44)
- Rapalogs Efficacy Relies on the Modulation of Antitumor T-cell Immunity. (2016) (43)
- Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB) (2019) (43)
- Complete histologic response induced by sorafenib in advanced hepatocellular carcinoma: a case report. (2011) (43)
- Patients' preference of trastuzumab administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: Results of the randomised MetaspHer study. (2017) (42)
- Squamous cell carcinoma of the head and neck: ESMO clinical Recommendations for diagnosis, treatment and follow-up. (2008) (42)
- Randomized phase II study of weekly versus every-3-week ixabepilone plus bevacizumab (ixa/bev) versus paclitaxel plus bev (pac/bev) as first-line therapy for metastatic breast cancer (MBC). (2010) (41)
- Clinical impact of targeted therapies in patients with metastatic clear-cell renal cell carcinoma (2014) (41)
- Sex differences in oncogenic mutational processes (2019) (41)
- Pertuzumab monotherapy following trastuzumab-based treatment: Activity and tolerability in patients with advanced HER2- positive breast cancer. (2016) (40)
- Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer. (2010) (40)
- Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study. (2017) (40)
- Cerebel (EGF111438): An Open Label Randomized Phase III Study Comparing the Incidence of CNS Metastases in Patients (PTS) with HER2+ Metastatic Breast Cancer (MBC), Treated with Lapatinib Plus Capecitabine (LC) Versus Trastuzumab Plus Capecitabine (TC) (2012) (39)
- [Breast cancer in the early stage]. (2012) (39)
- Cabazitaxel: a novel microtubule inhibitor. (2011) (39)
- Efficacy and safety of ixabepilone, a novel epothilone analogue. (2007) (39)
- Delayed care for patients with newly diagnosed cancer due to COVID-19 and estimated impact on cancer mortality in France (2021) (39)
- Is there still a role for triple endoscopy as part of staging for head and neck cancer? (2006) (38)
- Impact of STAT3 phosphorylation on the clinical effectiveness of anti-EGFR-based therapy in patients with metastatic colorectal cancer. (2013) (37)
- Clinical Prognostic Factors for Patients with Recurrent Head and Neck Cancer: Implications for Randomized Trials (2001) (37)
- A Randomized Phase I Pharmacokinetic Study Comparing Biosimilar Candidate SB3 and Trastuzumab in Healthy Male Subjects. (2016) (37)
- Final Overall Survival (OS) Results from the Randomised, Double-Blind, Placebo-Controlled, Phase III AVADO Study of Bevacizumab (BV) Plus Docetaxel (D) Compared with Placebo (PL) Plus D for the First-Line Treatment of Locally Recurrent (LR) or Metastatic Breast Cancer (mBC). (2009) (36)
- Concomitant b.i.d. radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in unresectable squamous-cell carcinoma of the pharynx: clinical and pharmacological data of a French multicenter phase II study. (1998) (36)
- Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2-positive breast cancer. (2019) (36)
- Phase II Trial of a Paclitaxel-Carboplatin Combination in Recurrent Squamous Cell Carcinoma of the Head and Neck (2000) (36)
- Impact of organised programs on colorectal cancer screening (2008) (36)
- Intra-operative intra-peritoneal chemotherapy with cisplatin in patients with peritoneal carcinomatosis of ovarian cancer (2009) (36)
- Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients. (2017) (35)
- Molecularly targeted agents: their promise as cancer chemopreventive interventions. (2005) (34)
- Cancer screening in France: subjects’ and physicians’ attitudes (2007) (34)
- Adjuvant T-DM1 versus Trastuzumab in Patients with Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer: Subgroup Analyses from KATHERINE. (2021) (33)
- MAINTENANCE HORMONAL TREATMENT IMPROVES PROGRESSION FREE SURVIVAL AFTER A FIRST LINE CHEMOTHERAPY IN PATIENTS WITH METASTATIC BREAST CANCER (2008) (33)
- Abstract S5-3: PHARE Trial results of subset analysis comparing 6 to 12 months of trastuzumab in adjuvant early breast cancer (2012) (32)
- Result of two randomized trials comparing nolatrexed (Thymitaq) versus methotrexate in patients with recurrent head and neck cancer. (2001) (32)
- Impact of everolimus blood concentration on its anti-cancer activity in patients with metastatic renal cell carcinoma (2014) (32)
- Impact of glycosylation on the effect of cytokines. A special focus on oncology. (2002) (32)
- Docetaxel chemotherapy induces transverse superficial loss of the nail plate. (1997) (31)
- An analysis of potential factors allowing an individual prediction of cisplatin-induced anaemia. (2000) (31)
- Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer (2019) (30)
- Abstract P2-16-04: Plasma Biomarker Analyses in the AVADO Phase III Randomized Study of First-Line Bevacizumab + Docetaxel in Patients with Human Epidermal Growth Factor Receptor (HER) 2-Negative Metastatic Breast Cancer (2010) (29)
- Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer. (2016) (29)
- Predictors of re-excision for positive or close margins in breast-conservation therapy for pT1 tumors. (2008) (28)
- Can treatment with Cocculine improve the control of chemotherapy-induced emesis in early breast cancer patients? A randomized, multi-centered, double-blind, placebo-controlled Phase III trial (2012) (28)
- Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer. (2009) (27)
- The efficacy of chemotherapy with docetaxel and paclitaxel in anthracycline-resistant breast cancer (Review). (1999) (27)
- Trastuzumab duration effects within patient prognostic subgroups in the PHARE trial. (2014) (26)
- Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine (2018) (26)
- In situ delivery of allogeneic natural killer cell (NK) combined with Cetuximab in liver metastases of gastrointestinal carcinoma: A phase I clinical trial (2018) (24)
- Economic impact of prescribing error prevention with computerized physician order entry of injectable antineoplastic drugs (2013) (24)
- Ribociclib (RIB) + fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): Results from MONALEESA-3 (2018) (24)
- A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer (2013) (24)
- A phase 2 randomized trial to evaluate the impact of a supervised exercise program on cardiotoxicity at 3 months in patients with HER2 overexpressing breast cancer undergoing adjuvant treatment by trastuzumab: design of the CARDAPAC study (2017) (23)
- Cisplatin Nephrotoxicity: A Multivariate Analysis of Potential Predisposing Factors (1997) (23)
- Breast cancer screening in France: results of the EDIFICE survey (2008) (22)
- Efficacy of trabectedin in metastatic solitary fibrous tumor (2011) (22)
- Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (22)
- A prospective characterization of the resolution of ixabepilone induced peripheral neuropathy: data from a large registrational program in patients with metastatic breast cancer. (2009) (22)
- Clinical benefit of bevacizumab (BV) plus first-line docetaxel (D) in elderly patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC): AVADO study. (2016) (22)
- Pan-European Expert Meeting on the Use of Metronomic Chemotherapy in Advanced Breast Cancer Patients: The PENELOPE Project (2019) (21)
- Organized colorectal cancer screening programmes: how to optimize efficiency among general practitioners (2011) (21)
- Prognostic and predictive indicators in early-stage breast cancer and the role of genomic profiling: Focus on the Oncotype DX® Breast Recurrence Score Assay. (2017) (21)
- Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study (2014) (20)
- Pertuzumab and Trastuzumab: Re-Responses to 2 Biological Agents in Patients with HER2-Positive Breast Cancer Which Had Previously Progressed during Therapy with Each Agent Given Separately: A New Biological and Clinical Observation. (2009) (20)
- Incidence and risk factors of anemia in patients with early breast cancer treated by adjuvant chemotherapy. (2012) (20)
- Hemodialysis does not affect everolimus pharmacokinetics: two cases of patients with metastatic renal cell cancer. (2012) (20)
- ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of squamous cell carcinoma of the head and neck. (2003) (20)
- Combination of Cisplatin‐Doxorubicin‐Cyclophosphamide in Adenocarcinoma of Unknown Primary Site: A Phase II Trial (2001) (19)
- In the era of genomics, should tumor size be reconsidered as a criterion for neoadjuvant chemotherapy? (2014) (19)
- Impact of general practitioners' sex and age on systematic recommendation for cancer screening (2011) (19)
- Improvement in intraperitoneal intraoperative cisplatin exposure based on pharmacokinetic analysis in patients with ovarian cancer (2008) (19)
- Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-analysis (2020) (19)
- A randomized, double-blind, phase III study comparing SB3 (trastuzumab biosimilar) with originator trastuzumab in patients treated by neoadjuvant therapy for HER2-positive early breast cancer. (2017) (19)
- Safety profile of new anticancer drugs (2010) (18)
- Abstract S6-5: Primary results of BEATRICE, a randomized phase III trial evaluating adjuvant bevacizumab-containing therapy in triple-negative breast cancer (2012) (18)
- A Randomized Phase I Study Comparing the Pharmacokinetics of HD201, a Trastuzumab Biosimilar, With European Union-sourced Herceptin. (2018) (18)
- Long-term follow-up of patients with metastatic breast cancer treated by trastuzumab: impact of institutions. (2014) (18)
- MONARCH 2: Abemaciclib in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer who progressed on endocrine therapy (2017) (18)
- Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study (2020) (18)
- MONARCH 2: Overall survival of abemaciclib plus fulvestrant in patients with HR+, HER2- advanced breast cancer (2019) (17)
- Safety and Efficacy of Cabazitaxel in the Docetaxel-Treated Patients with Hormone-Refractory Prostate Cancer (2012) (17)
- Phase II Trial of Paclitaxel–Epirubicin in Patients With Recurrent Soft-Tissue Sarcoma (2002) (17)
- Phase III Randomized Trial of Sunitinib (SU) vs. Capecitabine (C) in Patients (Pts) with Previously Treated HER2-Negative Advanced Breast Cancer (ABC). (2009) (17)
- Adverse events with pertuzumab and trastuzumab: Evolution during treatment with and without docetaxel in CLEOPATRA. (2012) (17)
- Primary lung sarcomas: long survivors obtained with iterative complete surgery. (2001) (17)
- Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy (2014) (16)
- A multicenter phase II study of XRP 6258 administered as a 1h i . v . infusion every 3 weeks in taxane-resistant metastatic breast cancer patients (2008) (16)
- Population pharmacokinetics of the humanised monoclonal antibody, HuHMFG1 (AS1402), derived from a phase I study on breast cancer (2010) (15)
- Results of PONDx, a prospective multicenter study of the Oncotype DX® breast cancer assay: Real-life utilization and decision impact in French clinical practice. (2019) (15)
- Switching between intravenous and subcutaneous trastuzumab: Safety results from the PrefHer trial. (2017) (15)
- Intraoperative chemotherapy with cisplatin and epinephrine after cytoreductive surgery in patients with recurrent ovarian cancer: a phase I study (2010) (15)
- Bevacizumab in First-Line Treatment of Metastatic Breast Cancer (2012) (15)
- Organized colorectal cancer screening programmes: how to optimize efficiency in the general population (2011) (15)
- Influence of capecitabine absorption on its metabolites pharmacokinetics: a bioequivalence study. (2008) (14)
- Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib + fulvestrant: Results from MONALEESA-3. (2018) (14)
- Phare Trial Results Comparing 6 to 12 Months of Trastuzumab in Adjuvant Early Breast Cancer (2012) (14)
- Phase II trial of ixabepilone in patients with metastatic breast cancer (MBC) who are resistant to an anthracycline, a taxane and capecitabine. (2006) (14)
- Cost–utility analyses of drug therapies in breast cancer: a systematic review (2016) (14)
- Cancer Therapy : Clinical Analysis of Spontaneous Tumor-Speci fi c CD 4 T-cell Immunity in Lung Cancer Using Promiscuous HLA-DR Telomerase-Derived Epitopes : Potential Synergistic Effect with Chemotherapy Response (2012) (14)
- Impact of sunitinib pharmacokinetic monitoring in a patient with metastatic renal cell carcinoma undergoing hemodialysis. (2011) (14)
- Prospective study of the impact of using the 21-gene recurrence score assay on clinical decision making in women with estrogen receptor-positive, HER2-negative, early-stage breast cancer in France. (2012) (13)
- Clinical and economic impact of epoetin in adjuvant-chemotherapy for breast cancer (2006) (13)
- [Economic assessment of the routine use of Oncotype DX® assay for early breast cancer in Franche-Comte region]. (2014) (13)
- Breast cancer screening in women aged 50–74 years: isthereroom for improvement? (2011) (13)
- First-Line Vinorelbine-Mitoxantrone Combination in Metastatic Breast Cancer Patients Relapsing after an Adjuvant Anthracycline Regimen: Results of a Phase II Study (1998) (13)
- Myotax: a phase II trial of docetaxel plus non-pegylated liposomal doxorubicin as first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines. (2011) (12)
- Chemotherapy impairs skeletal muscle mitochondrial homeostasis in early breast cancer patients (2022) (12)
- Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes (2016) (12)
- Pharmacokinetics of low-dose carboplatin and applicability of a method of calculation for estimating individual drug clearance. (2003) (12)
- Cancer screening in France: third edition of the EDIFICE survey (2015) (12)
- Sequential taxane and anthracycline-containing neoadjuvant regimens: the sequential order impact. (2011) (12)
- Challenges in the implementation of trastuzumab biosimilars: an expert panel’s recommendations (2015) (12)
- Is extracapsular tumour spread a prognostic factor in patients with early breast cancer? (2013) (12)
- Adjuvant Subcutaneous Trastuzumab for HER2-Positive Early Breast Cancer: Subgroup Analyses of Safety and Active Medical Conditions by Body Weight in the SafeHer Phase III Study. (2018) (12)
- Intraperitoneal clearance as a potential biomarker of cisplatin after intraperitoneal perioperative chemotherapy: a population pharmacokinetic study (2011) (11)
- Peripheral neuropathy (PN), thrombocytopenia (TCP) and central nervous system (CNS) recurrence: An update of the phase III KATHERINE trial of post-neoadjuvant trastuzumab emtansine (T-DM1) or trastuzumab (H) in patients (pts) with residual invasive HER2-positive breast cancer (BC) (2019) (11)
- GWAS in the SIGNAL/PHARE clinical cohort restricts the association between the FGFR2 locus and estrogen receptor status to HER2-negative breast cancer patients (2016) (11)
- Feasibility of health-related quality of life (HRQoL) assessment for cancer patients using electronic patient-reported outcome (ePRO) in daily clinical practice (2021) (11)
- Abstract P6-12-02: A Randomized Phase II Study of Sunitinib vs. Standard of Care for Patients with Previously Treated Advanced Triple-Negative Breast Cancer (2010) (10)
- Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics (2019) (10)
- Lung cancer risks, beliefs and healthcare access among the underprivileged (2015) (10)
- Follow-up of patients with localized breast cancer and first indicators of advanced breast cancer recurrence: A retrospective study. (2017) (10)
- Author Correction: Landscape of somatic mutations in 560 breast cancer whole-genome sequences (2019) (10)
- Phase III, randomized study of first-line trastuzumab emtansine (T-DM1) ± pertuzumab (P) vs. trastuzumab + taxane (HT) treatment of HER2-positive MBC: Final overall survival (OS) and safety from MARIANNE. (2017) (10)
- LBA11 Individual patient data meta-analysis of 5 non-inferiority RCTs of reduced duration single agent adjuvant trastuzumab in the treatment of HER2 positive early breast cancer (2021) (10)
- Social stratification, risk factor prevalence and cancer screening attendance (2015) (10)
- Immunomodulatory Effects of Everolimus in a Long Responsive Patient With Metastatic Renal Cell Carcinoma (2014) (10)
- [Cost effectiveness of Ligasure Precise versus surgical clips during axillary nodal dissection for breast cancer]. (2006) (10)
- Adjuvant chemotherapy for local relapse breast cancer. (2014) (10)
- Phase II study assessing lapatinib added to letrozole in patients with progressive disease under aromatase inhibitor in metastatic breast cancer—Study BES 06 (2013) (9)
- Safety Results and Analysis of Eribulin Efficacy according to Previous Microtubules-Inhibitors Sensitivity in the French Prospective Expanded Access Program for Heavily Pre-treated Metastatic Breast Cancer (2017) (9)
- First description of a sporadic breast cancer in a woman with BRCA1 germline mutation (2015) (9)
- Age, Neurological Status MRC Scale, and Postoperative Morbidity are Prognostic Factors in Patients with Glioblastoma Treated by Chemoradiotherapy (2016) (9)
- Optimal Physicochemical Properties of Antibody–Nanoparticle Conjugates for Improved Tumor Targeting (2022) (9)
- Response Rates: A Valuable Signal of Promising Activity? (2009) (9)
- Extravasation of liposomal doxorubicin induces irritant reaction without vesicant injury. (2012) (9)
- Mammography utilization in women aged 40–49 years: the French EDIFICE survey (2011) (9)
- Economic impact of simplified de Gramont regimen in first-line therapy in metastatic colorectal cancer (2006) (9)
- Breast cancer, locally advanced and metastatic (2012) (9)
- A new era for treatment development in HER2-positive breast cancer. (2018) (9)
- Results of randomised phase II studies comparing S16020 with methotrexate in patients with recurrent head and neck cancer. (2003) (9)
- Fluctuation of the left ventricular ejection fraction in patients with HER2-positive early breast cancer treated by 12 months of adjuvant trastuzumab. (2018) (9)
- Liposomal encapsulation of trans-crocetin enhances oxygenation in patients with COVID-19-related ARDS receiving mechanical ventilation (2021) (9)
- Abstract 4447: In search of the ideal cancer screening test (2012) (9)
- First description of a double heterozygosity for BRCA1 and BRCA2 pathogenic variants in a French metastatic breast cancer patient: A case report. (2017) (8)
- Ixabepilone, a novel epothilone analog in the treatment of breast cancer (2008) (8)
- A Retrospective Study of Bifractionated CPT-11 With LF5FU Infusion (FOLFIRI-3) in Colorectal Cancer Patients Pretreated With Oxaliplatin and CPT-11 Containing Chemotherapies (2008) (8)
- Awareness and Misconceptions of Breast Cancer Risk Factors Among Laypersons and Physicians (2018) (8)
- Combining molecular targeted therapies: clinical experience (2011) (8)
- [Epidermal growth factor receptors (EGFR): a new target for anticancer therapy]. (2003) (8)
- Abstract P4-12-11: Patient preference for subcutaneous trastuzumab via handheld syringe versus intravenous infusion in HER2-positive early breast cancer: Cohort 2 of the PrefHer study (2013) (8)
- Impact of awareness of cancer among acquaintances on cancer screening attendance (2011) (8)
- [Induction chemotherapy in patients with head and neck cancer]. (2006) (8)
- Impact of COVID‐19 and lockdown regarding blood transfusion (2021) (8)
- Prostate cancer screening: contrasting trends (2015) (8)
- [Safety and efficacy of bevacizumab combined with taxanes in the first-line treatment of metastatic breast cancer: ATHENA study-France]. (2012) (8)
- Fulvestrant and palbociclib combination in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer patients (2019) (8)
- Total pathologic complete response (tpCR) and event-free survival (EFS) with subcutaneous (SC) or intravenous (IV) trastuzumab in HER2-positive early breast cancer (EBC). (2015) (7)
- 153PDOne-year safety, immunogenicity, and survival results from a phase III study comparing SB3 (a proposed trastuzumab biosimilar) and originator trastuzumab in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment (2017) (7)
- Manual injection of subcutaneous trastuzumab vs intravenous infusion for HER2-positive early breast cancer: a time-and-motion study (2013) (7)
- Cardiac safety of the lapatinib/letrozole combination as first-line therapy in patients (pts) with metastatic breast cancer (MBC). (2016) (7)
- Breast cancer screening controversy: too much or not enough? (2015) (7)
- Metronomic cyclophosphamide therapy in hormone-naive patients with non-metastatic biochemical recurrent prostate cancer: a phase II trial (2016) (7)
- Can we establish a hierarchy among trastuzumab biosimilar candidates? (2018) (7)
- Real-world patient-reported outcomes of women receiving initial endocrine-based therapy for HR+/HER2− advanced breast cancer in five European countries (2020) (7)
- Critical appraisal of health-state utility values used in breast cancer-related cost–utility analyses (2017) (7)
- [Combination of mitoxantrone-vinorelbine as first-line chemotherapy for metastatic breast carcinoma]. (1995) (7)
- Beliefs and behavior regarding e-cigarettes in a large cross-sectional survey (2018) (7)
- Wound healing is not impaired by the epidermal growth factor receptor-tyrosine kinase inhibitor gefitinib (2003) (7)
- Subcutaneous Injection of Trastuzumab – Analysis of Administration Time and Injection Site Reactions (2012) (7)
- Transmission of breast cancer polygenic risk based on single nucleotide polymorphisms. (2018) (6)
- Renal safety of ibandronate 6 mg infused over 15 min versus 60 min in breast cancer patients with bone metastases: a randomized open-label equivalence trial. (2011) (6)
- Efficacy of HD201 vs Referent Trastuzumab in Patients With ERBB2-Positive Breast Cancer Treated in the Neoadjuvant Setting (2022) (6)
- Ixabepilone, a novel epothilone analog in the treatment of breast cancer. (2008) (6)
- A multivariate analysis for predicting cisplatin-induced delayed emesis. (2000) (6)
- Liver Metastases from Head and Neck Squamous Cell Carcinomas: Radiological and Biological Features (2004) (6)
- First-line bevacizumab plus taxane-based chemotherapy for metastatic breast cancer: cost-minimisation analysis. (2012) (6)
- Evaluation of trastuzumab (Herceptin®), docetaxel and capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer (2007) (6)
- Biologic Drug Quality Assurance to Optimize HER2 + Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3 (2020) (6)
- A prognostic factor (PF) index for overall survival in a HER2-negative endocrine-resistant metastatic breast cancer (MBC) population: Analysis from the ATHENA trial. (2013) (6)
- Persistent taxane‐induced neuropathy in elderly patients treated for localized breast cancer (2020) (6)
- Impact of Chemotherapy Beyond the Third Line in Patients With Recurrent Epithelial Ovarian Cancer (2015) (6)
- Gastrointestinal tumors, non-colorectal (2012) (6)
- Uptake of breast cancer screening in women aged over 75years: a controversy to come? (2011) (5)
- Trastuzumab plus docetaxel with or without capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer: a randomised Phase II study (2008) (5)
- Fluctuating Behavior of the French Population in Cancer Screening: 5th Edition of the EDIFICE Survey (2018) (5)
- Abstract GS2-07: PHARE randomized trial final results comparing 6 to 12 months of trastuzumab in adjuvant early breast cancer (2019) (5)
- A phenotypic and mechanistic perspective on heterogeneity of HER2-positive breast cancers (2016) (5)
- Screening for prostate cancer: growth without control (2011) (5)
- Systemic high-dose intravenous methotrexate in patients with central nervous system metastatic breast cancer (2019) (5)
- Safeher: A Study of Assisted- and Self-Administered Subcutaneous Trastuzumab (H-SC) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (EBC) (2012) (5)
- Prolonged overall survival for patients with bone-only metastases at presentation of metastatic breast cancer. (2018) (5)
- Specific anticancer treatments in the last 3 months of life: a French experience (2013) (5)
- P4-17-03: Incidence Rate of Asymptomatic Brain Metastases in Patients with HER2+ Metastatic Breast Cancer Screened for EGF111438/CEREBEL Study. (2011) (5)
- Vulnerable populations and overconfidence in cancer screening. (2014) (5)
- Population pharmacokinetic and pharmacodynamic modeling of capecitabine and its metabolites in breast cancer patients (2021) (5)
- 2089 POSTER Clinical impact of upfront adjuvant AI therapy on the early risk of recurrence (2007) (5)
- [Cancer screening in France: 10 years of analysis of behaviours by the EDIFICE surveys]. (2017) (4)
- Evolution in the real-world therapeutic strategies in more than 20,000 women with breast cancer having received human epidermal growth factor receptor 2-targeted treatments: Results from the french personalized reimbursement model database (2011-2018). (2020) (4)
- [Edifice program: analysis of screening exam practices for cancer in France]. (2008) (4)
- Abstract P3-15-04: A French prospective pilot study to identify dihydropyrimidine dehydrogenase (DPD) deficiency in breast cancer patients receiving capecitabine (2013) (4)
- Superimposable outcomes for sequential and concomitant administration of adjuvant trastuzumab in HER2-positive breast cancer: Results from the SIGNAL/PHARE prospective cohort. (2017) (4)
- First-line trastuzumab plus taxane-based chemotherapy for metastatic breast cancer: Cost-minimization analysis (2014) (4)
- Hemodialysis does not affect everolimus pharmacokinetics: two cases of patients with metastatic renal cell cancer. (2012) (4)
- P103 Subcutaneous trastuzumab plus chemotherapy for early breast cancer: interim safety from SafeHer (2015) (4)
- Safety of First-Line Letrozole Compared with Lapatinib Plus Letrozole in Patients with Postmenopausal Hormone Receptor Positive Metastatic Breast Cancer: EGF30008 Study. (2009) (4)
- Duration: escalation study of oral etoposide with carboplatin in patients with varied solid tumors (2010) (4)
- Population Pharmacokinetics and Dosing Recommendations for Cisplatin during Intraperitoneal Peroperative Administration (2009) (4)
- A French prospective pilot study for identifying dihydropyrimidine dehydrogenase (DPD) deficiency in breast cancer patients (pts) receiving capecitabine (cap) (2013) (4)
- [Bevacizumab and taxanes in the first-line treatment of metastatic breast cancer : overall survival and subgroup analyses of the ATHENA study in France]. (2014) (4)
- Impact of platinum complexes on dihydropyrimidine dehydrogenase activity in 5-fluorouracil-treated patients. (2003) (4)
- 1BA Subcutaneous Administration of Trastuzumab in Patients with HER2-positive Early Breast Cancer: Results From the Phase III Randomised, Open-label, Multi-centre Neoadjuvant-adjuvant HannaH Study (2012) (4)
- Protective effect of intra-peritoneal epinephrine on postoperative renal function after cisplatin-based intra-peritoneal intra-operative chemotherapy. (2011) (4)
- 299PEribulin is safe and efficient in metastatic breast cancer in elderly patients. Results from the REPROLINE multicentric retro-prospective cohort (2017) (4)
- Incidental axillary dose delivery to axillary lymph node levels I–III by different techniques of whole-breast irradiation: a systematic literature review (2021) (4)
- A dose-escalating study of XRP6258 in combination with capecitabine, in patients (pts) with metastatic breast cancer (MBC) progressing after anthracycline and taxane therapy: Preliminary results. (2009) (4)
- Ixabepilone: A New Active Chemotherapy in the Treatment of Breast Cancer (2009) (4)
- Arthralgia and aromatase inhibitors. (2014) (4)
- F12 How safe is bevacizumab for elderly patients (2009) (4)
- Cancer screening: Source of information and level of trust. (2012) (4)
- Biomarker (BM) Results from the Phase III Averel Trial of 1st-Line Bevacizumab (BV), Trastuzumab (H) + Docetaxel (T) for HER2-Positive Locally Recurrent/Metastatic Breast Cancer (LR/MBC) (2012) (4)
- Evolution of Physical Status From Diagnosis to the End of First-Line Treatment in Breast, Lung, and Colorectal Cancer Patients: The PROTECT-01 Cohort Study Protocol (2020) (4)
- Exhaustive single nucleotide polymorphism (SNP) analysis of DPYD exome in breast cancer patients (pts) receiving capecitabine (2015) (4)
- [Vertebral osteosarcoma. Review of the literature apropos of a case]. (1995) (3)
- Anthracycline-resistant breast cancer (1997) (3)
- Splenic lymphoma with villous lymphocytes: dissociated response with fludarabin. (1999) (3)
- Phase I and pharmacokinetic study of capecitabine and cisplatin in head and neck cancer patients (2001) (3)
- Abstract P5-15-07: Time savings with trastuzumab subcutaneous (SC) injection vs. trastuzumab intravenous (IV) infusion: First results from a Time-and-Motion study (T&M) (2012) (3)
- Abstract PD3-11: Efficacy and safety of subcutaneous or intravenous trastuzumab in patients with HER2-positive early breast cancer after 5 years' treatment-free follow-up: Final analysis from the phase III, open-label, randomized HannaH study (2018) (3)
- ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of squamous cell carcinoma of the head and neck (SCCHN). (2005) (3)
- B.i.d. radiotherapy and chemotherapy with CDDP/5-FU in unresectable pharyngeal carcinoma: 10 years experience at the centre antoine-lacassagne. impact of tumoral EGFR level on response and survival (2001) (3)
- Melanoma risk‐takers: fathers and sons (2015) (3)
- Cost-Effectiveness Analysis of Tyrosine Kinase Inhibitors for Patients with Advanced Gastrointestinal Stromal Tumors (2016) (3)
- New Microtubule Inhibitors in Breast Cancer (2013) (3)
- 284PReal-life study of BRCA genetic screening in metastatic breast cancer (2017) (3)
- TROIKA‐1: A double‐blind, randomized, parallel group, study aimed to demonstrate the equivalent pharmacokinetic profile of HD201, a potential biosimilar candidate to trastuzumab, versus EU‐Herceptin® and US‐Herceptin® in healthy male subjects (2021) (3)
- Cancer screening in France: Reaching a plateau? New edition of an iterative nationwide survey. (2015) (3)
- Enterocolitis in Patients with Cancer Treated with Docetaxel. (2018) (3)
- Increasing Coverage Rates for Mammographic Screening in France in Older Women––16 Years of Follow‐Up (2011) (3)
- Cancer screening tests in France: First results of EDIFICE study. (2006) (3)
- Abstract S1-01: Analysis of molecular prognostic factors associated with tumor immune and stromal microenvironment in BEATRICE, an open-label phase 3 trial in early triple-negative breast cancer (eTNBC) (2016) (3)
- Constitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohort (2017) (3)
- P201 Subcutaneous versus intravenous trastuzumab in early breast cancer: 2-year follow-up of HannaH (2015) (3)
- Treatment-Induced Acute Leukaemia after Major Response to Cyclophosphamide-Based Metronomic Chemotherapy in Refractory Heavily Pre-Treated Prostate Cancer (2013) (3)
- 445 PrefHer: a Clinical Trial to Evaluate Patient Preference for Trastuzumab Administered Subcutaneously or Intravenously in Patients with HER2-positive Early Breast Cancer (2012) (3)
- First-line lapatinib combined with letrozole versus letrozole alone for hormone receptor positive (HR+) metastatic breast cancer (MBC): Subgroup analyses of borderline FISH+, IHC 2+, HER2 unknown (UNK), and treatment-naive (TN) populations from EGF30008. (2009) (3)
- [Efficacy, safety and cost of eribulin in patients with metastatic breast cancer]. (2015) (3)
- 21PD_PRPERCEPTION OF LUNG CANCER (LC) RISK: IMPACT OF SMOKING STATUS AND NICOTINE DEPENDENCE (2015) (3)
- Adjuvant Trastuzumab Is Required in Human Epidermal Growth Factor Receptor 2-Positive Node-Negative Breast Cancer Patients Regardless of Tumour Size (2020) (2)
- Safety of surgery in patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC) treated with docetaxel (D) plus bevacizumab (BV) or placebo (PL) in the AVADO phase III study. (2009) (2)
- Evaluation of survival by ADCC status: Subgroup analysis of SB3 (Trastuzumab Biosimilar) and reference trastuzumab in patients with HER2-positive early breast cancer at three-year follow-up. (2019) (2)
- Knowledge of the French population on colorectal cancer screening: Data from the EDIFICE 3 survey. (2013) (2)
- Neuropilin-2 and epithelial to mesenchymal transition in colorectal cancer cells. (2010) (2)
- 154P Five-year follow-up of the phase III study comparing SB3 (trastuzumab biosimilar) and reference trastuzumab in patients with HER2 positive early or locally advanced breast cancer (2021) (2)
- 5077 Lapatinib plus letrozole vs. letrozole alone in patients (pts) with endocrine sensitive, HER2+, previously untreated metastatic breast cancer (MBC) with multiple (>3sites) or liver metastases (2009) (2)
- Abstract CT055: A randomized, double-blinded, controlled study of tucatinib (ONT-380) vs. placebo in combination with capecitabine (C) and trastuzumab (Tz) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (MBC) (HER2CLIMB) (2017) (2)
- Phase II trial of paclitaxel and uracil--tegafur in metastatic breast cancer. TEGATAX trial. (2011) (2)
- Adjuvant subcutaneous trastuzumab for HER2-positive early breast cancer: Phase III SafeHer study subgroup analyses of body weights, active medical conditions, safety and tolerability (2016) (2)
- Appropriate cytotoxic drugs usages in solid tumors: Impact of appropriate use referentials (2012) (2)
- Abstract P6-11-04: Capecitabine Therapy for Locally Advanced or Metastatic Breast Cancer: A Difference between Reported Clinical Trials and Routine Clinical Practice? Results from the ELIXIR Study in Routine Oncology Practice (2010) (2)
- Real-world clinical profile, treatment patterns and patient-reported outcomes in a subset of HR+/HER2- advanced breast cancer patients with poor prognostic factors: data from an international study (2021) (2)
- Clinical activity of the novel epothilone B analog, ixabepilone, in triple negative breast cancer (BC) patients (2008) (2)
- Cardiotoxicity is mitigated after a supervised exercise program in HER2-positive breast cancer undergoing adjuvant trastuzumab (2022) (2)
- Anticancer therapy in patients with porphyrias: evidence today. (2008) (2)
- Patient-reported outcomes (PROs) from MARIANNE: A phase III study of trastuzumab emtansine (T-DM1) +/- pertuzumab (P) vs trastuzumab + taxane (HT) for HER2-positive advanced breast cancer. (2016) (2)
- Abstract P6-17-09: Event-free survival by ADCC status from a follow-up study comparing SB3 (trastuzumab biosimilar) with reference trastuzumab for HER2 positive breast cancer in neoadjuvant setting (2019) (2)
- Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer (2019) (2)
- A phase 2 randomized, double-blinded, controlled study of ONT-380 vs. placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (MBC) (2016) (2)
- Classic cytotoxic drugs: a narrow path for regulatory approval. (2017) (2)
- Development of skeletal muscle atrophy and intermuscular adipose tissue in patients with early breast cancer treated with chemotherapy (2022) (2)
- [Severe hypocalcemia after treatment with diphosphonates and aminoglycosides]. (1994) (2)
- Clinical activity of ixabepilone, a novel epothilone b analog, across the breast cancer disease continuum (2008) (2)
- Can adjuvant homeopathy improve the control of post-chemotherapy emesis in breast cancer patients? Results of a randomized placebo-controlled trial. (2009) (2)
- Safety and efficacy of adjuvant subcutaneous trastuzumab in human epidermal growth factor receptor 2-positive early breast cancer: Final results of the SafeHER study (2022) (2)
- Breast cancer screening controversy: Impact on other cancer screening programs. (2014) (2)
- Special Lecture Anthracycline-Resistant Breast Cancer (1997) (1)
- 5059 POSTER Systemic High-dose Intravenous Methotrexate for Central Nervous System Metastases in Breast Cancer (2011) (1)
- Cancer screening in France: 3rd edition of the EDIFICE survey. (2012) (1)
- Emilia: use cunning to survive cancer. (2018) (1)
- [Immunotherapy: an emerging strategies against prostate castration resistant cancer]. (2012) (1)
- Abstract 2751: Impact of germinal vascular endothelial growth factor-A (VEGF-A) gene polymorphisms on pharmacodynamics of bevacizumab in metastatic breast cancer patients treated as first-line therapy : A French companion study of the open label international multicenter MO19391 trial (2010) (1)
- [Overall survival and survival without local recurrence in case of radiotherapy of the tumor bed of ductal carcinomas in situ of the breast: review of the literature.] (2021) (1)
- [Cancer of the larynx and the hypopharynx: anatomy, anatomopathology, clinical signals, TNM, therapy]. (2000) (1)
- [KIT and KIT: from biology to clinical use]. (2012) (1)
- Novel Cytotoxic Agents in Chemotherapy-resistant Metastatic Breast Cancer – The Epothilones (2008) (1)
- Author Correction: Pan-cancer analysis of whole genomes (2023) (1)
- Early skeletal muscle deconditioning and reduced exercise capacity during (neo)adjuvant chemotherapy in patients with breast cancer (2022) (1)
- Prevention and screening (2012) (1)
- Ongoing clinical development of lapatinib in HER2-positive (HER2+) metastatic breast cancer (MBC): An innovative approach to recruit patients in clinical studies. (2011) (1)
- Organizing medical oncology care at a regional level and its subsequent impact on the quality of early breast cancer management: a before-after study (2014) (1)
- Cancer Screening in Underserved, Vulnerable Population. Results from the Edifice Survey (2012) (1)
- Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy? (2008) (1)
- [Duodenal Burkitt lymphoma in an HIV-negative patient: a medical emergency]. (2000) (1)
- Abstract P5-18-22: Long-term survival of patients with HER2 metastatic breast cancer treated by targeted therapies. (2012) (1)
- Cytoreductive Surgery and Intraperitoneal Chemotherapy in Advanced Serous Epithelial Ovarian Cancer: A 14-Year French Retrospective Single-Center Study of 124 Patients (2022) (1)
- Anticancer therapy in patients with porphyrias: evidence today (2008) (1)
- 2119 POSTER Clinical activity of the novel epothilone B analog, ixabepilone, across the breast cancer disease continuum (2007) (1)
- An open-label, multinational, multicentre, phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients with HER2-positive early or metastatic breast cancer (UmbHER1): Interim safety results from early breast cancer studies (2016) (1)
- 1945 Phase III HannaH study of subcutaneous or intravenous trastuzumab for HER2-positive early breast cancer: Exploratory subgroup analyses of pathological complete response and 3-year event-free survival according to body weight and anti-drug antibody status (2015) (1)
- [Value of neo-angiogenesis evaluation in cancer of the breast]. (1996) (1)
- 5025 A dose escalating study of cabazitaxel (XRP6258) in combination with capecitabine, in patients (pts) with metastatic breast cancer (MBC) progressing after anthracycline and taxane therapy (2009) (1)
- Cardiac Safety and Efficacy of SB3 Trastuzumab Biosimilar for ERBB2-Positive Early Breast Cancer (2023) (1)
- Four-year follow-up of a phase III study comparing SB3 (trastuzumab biosimilar) and reference trastuzumab in HER2-positive early or locally advanced breast cancer in neoadjuvant setting. (2020) (1)
- Trends in screening for colorectal cancer in France. (2016) (1)
- 990PDIMPACT OF CLINICAL PRACTICE GUIDELINE'S ON MEDICAL PRACTICE AND SURVIVAL FOR HEAD AND NECK CANCER MANAGEMENT IN FISRT LINE TREATMENT (N = 1121 PATIENTS). (2014) (1)
- 55O_PRPhase III HannaH study of subcutaneous or intravenous trastuzumab for HER2-positive early breast cancer: Exploratory subgroup analyses of pathological complete response and 3-year event-free survival by body weight and anti-drug antibody status (2015) (1)
- Anti‐BCMA Immuno‐NanoPET Radiotracers for Improved Detection of Multiple Myeloma (2021) (1)
- PCN12 IMPACT OF ADJUVANT CHEMOTHERAPY WITH DOCETAXEL FOR EARLY BREAST CANCER: COST-EFFECTIVENESS ANALYSIS (CEA) OF A DOCETAXEL, DOXORUBICIN AND CYCLOPHOSPHAMIDE REGIMEN (TAC) VERSUS 5-FLUOROURACIL, DOXORUBICIN AND CYCLOPHOSPHAMIDE (FAC) IN FRANCE (2005) (1)
- [Breast cancer in two male dizygotic twins]. (2000) (1)
- [Prevalence and management of pain in patients with metastatic cancer in Franche-Comté]. (2016) (1)
- Real-world study on HR+, HER2−, node-positive, high-risk early breast cancer (EBC) in France: patient profiles, management and treatment patterns (2021) (1)
- Leveraging Immunotherapy with Nanomedicine (2020) (1)
- MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2−-Advanced Breast Cancer (2021) (1)
- Beliefs and behavior regarding e-cigarettes in a large cross-sectional survey. (2015) (1)
- MONARCH 2: subgroup analysis of patients receiving abemaciclib+fulvestrant as first- and second-line therapy for HR+, HER2- advanced breast cancer (ABC) (2020) (1)
- The open-label, multinational, multicenter, Phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients (pts) with HER2-positive early breast cancer (EBC) or metastatic breast cancer (MBC): Pooled analysis of safety data from the UmbHER1 program. (2018) (1)
- Cervical cancer: Awareness and misconceptions of risk factors among lay persons and physicians (2016) (1)
- Screening for colorectal cancer in France: Third edition of the EDIFICE survey. (2012) (1)
- Awareness and misconceptions of colorectal cancer risk factors among laypersons and physicians. (2017) (1)
- [Chemotherapy for patients with local-regional recurrent or metastatic carcinoma of the head and neck]. (2003) (1)
- Docetaxel, Cisplatin and Fluorouracil as Perioperative Chemotherapy in Resectable Gastroesophageal Carcinoma: a Retrospective Analysis (2012) (1)
- Low correlation between Ki67 assessed by qRT-PCR in Oncotype Dx score and Ki67 assessed by Immunohistochemistry (2022) (1)
- 1865 Activity and toxicity profile of eribulin mesylate in heavily pretreated metastatic breast cancer: An observational study (EVHALAVEN) (2015) (1)
- Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study (2014) (1)
- Microenvironment and Immunology Novel Role for STAT 3 in Transcriptional Regulation of NK Immune Cell Targeting Receptor MICA on Cancer Cells (2011) (1)
- The Personalised Reimbursement Models (Prm): Real World Data Collection to Provide Innovative Pricing Solutions in France (2017) (1)
- A propensity score–weighted study comparing a two- versus four-weekly pegylated liposomal doxorubicin regimen in metastatic breast cancer (2022) (1)
- Squamous cell carcinoma of the head and neck: ESMO clinical recommendations for diagnosis, treatment and follow-up. (2007) (1)
- Author Correction: Landscape of somatic mutations in 560 breast cancer whole-genome sequences (2019) (1)
- 1363PSCREENING FOR BREAST CANCER. FEAR AND REASSURANCE: IMPACT OF THE RECENT CONTROVERSY. (2014) (1)
- [Appropriate cytotoxic drug usages in solid tumors: conformity to official labelling and level of scientific evidence]. (2006) (1)
- Abstract P3-08-01: MONARCH 2: Interim analysis of overall survival in patients with poor prognostic factors (2020) (0)
- 1956 Safety and tolerability of subcutaneous trastuzumab for HER2-positive early breast cancer in patients with lower body weight and in Asian patients: SafeHer Phase III study subgroup analyses (2015) (0)
- Adjuvant Trastuzumab for 6 versus 12 Months in Patients with Early Breast Cancer (2012) (0)
- Additional one-year follow-up study to evaluate safety and survival in patients who have completed neoadjuvant-adjuvant treatment with SB3 (trastuzumab biosimilar) or reference trastuzumab in HER2-positive early or locally advanced breast cancer. (2018) (0)
- Exacerbated central fatigue and reduced exercise capacity in early-stage breast cancer patients treated with chemotherapy. (2023) (0)
- Clinical validation of pneumatic transportation systems for monoclonal antibodies (2023) (0)
- Final efficacy results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer (2015) (0)
- Abstract P6-14-01: Final results of the TANIA randomized phase III trial of bevacizumab (BEV) after progression on 1st-line BEV therapy for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC) (2016) (0)
- Abstract P6-07-13: New insights on HER2 amplification from the constitutional and somatic standpoints: Results from the ICGC and SIGNAL/Phare studies (2016) (0)
- Abstract A88: Cancer awareness through close circle experience of the disease: An increasing trend (2010) (0)
- A Combination of Native LC-MS Approaches for the Comprehensive Characterization of the Antibody-Drug Conjugate Trastuzumab Deruxtecan. (2022) (0)
- HD201: Analytical biocomparability and clinical trial progression of trastuzumab. (2019) (0)
- LBA15SToRM: A clinical cohort to identify genetic variability related to metastatic phenotypes (2017) (0)
- Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: final analysis of the randomised, two-cohort PrefHer study (2016) (0)
- 3504 General Practitioner's attitudes towards cancer screening – Does gender still matter? (2009) (0)
- Subgroup analyses of efficacy from a phase III study comparing SB3 (trastuzumab biosimilar) with reference trastuzumab in early breast cancer patients. (2018) (0)
- Ribociclib (RIB) + fulvestrant (FUL) for advanced breast cancer (ABC): Progression-free survival (PFS) subgroup and tumor response analyses from MONALEESA-3. (2018) (0)
- Reply to the letter to the editor 'patients' preference and informed consent' by Pumo et al. (2015) (0)
- 286P Outcome of patients with HER2-positive brain metastatic breast cancer: A 10-year retrospective study (2021) (0)
- [Efficacy and safety of ixabepilone (BMS-247550), a novel epothilone B analogue]. (2008) (0)
- PONDx, Prospective Multicenter Study of the Oncotype DX Breast Cancer assay: real-life utilization in French clinical practice (2017) (0)
- Superimposable outcomes for sequential and concomitant administration of adjuvant trastuzumab in HER2-positive breast cancer: Results from the SIGNAL/PHARE prospective cohort (2016) (0)
- Impact of organization of colorectal cancer screening: Results of EDIFICE study. (2006) (0)
- The Place of Chemotherapy in The Evolving Treatment Landscape for Patients With HR-positive/HER2-negative MBC. (2021) (0)
- Overall survival according to tumoral clusterin expression in breast cancer. (2013) (0)
- Can we establish a hierarchy among trastuzumab biosimilar candidates? (2018) (0)
- [Primary adenocarcinoma of the lacrimal glands. A case]. (1994) (0)
- Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer (2019) (0)
- P1.03-040 Beliefs Surrounding Lung Cancer Screening among Physicians and Lay Populations: Results from the EDIFICE Survey: Topic: Screening (2017) (0)
- Abstract P2-04-05: Pros and cons of breast cancer screening: Knowledge in lay women (2013) (0)
- 1365PBREAST CANCER SCREENING CONTROVERSY: IMPACT ON OTHER CANCER SCREENING PROGRAMS. (2014) (0)
- Reply to the letter to the editor 'Patients' preference and informed consent' by Pumo et al. (2015) (0)
- The efficacy of everolimus relies on a modulation of adaptative anti tumor T cell immunity (2016) (0)
- 63PPhase III SafeHer study subgroup analyses: Safety and tolerability of subcutaneous trastuzumab for HER2-positive early breast cancer in patients with lower body weight and in Asian patients (2015) (0)
- 1209 Lung cancer screening: Who should pay? Results from a nationwide survey (2015) (0)
- 5069 POSTER Phase II Study Assessing Lapatinib Added to Letrozole in Patients With Progressive Disease Under Aromatase Inhibitor in Metastatic Breast Cancer – Study BES 06 (2011) (0)
- Trends in screening for prostate cancer. (2016) (0)
- Meat consumption and cancer risk : is the de fi nition of red meat always suitable ? (2012) (0)
- MTA (Multi-Targeted Antifolate, LY231514) (1999) (0)
- 5-year follow-up of the safety, tolerability and efficacy of subcutaneous trastuzumab for the adjuvant treatment of HER2-positive early breast cancer. Results from the SafeHER Phase III trial (2021) (0)
- Ki67 Assessment by qRT-PCR in OncotypeDx ® Breast Recurrent Score®: Low Correlation With IHC Assessment of ki67 and Prognostic Impact of ki67 RNA Level of Expression. (2021) (0)
- Author Correction: Inferring structural variant cancer cell fraction (2022) (0)
- 121 Is the usefulness of routine triple endoscopy for head and neck cancer patients debatable (2003) (0)
- 1101 Less cancer screening in the vulnerable population? Results from the EDIFICE 4 survey (2015) (0)
- Antitumor Immunity Implications in Graft-versus-Host Disease Regulatory Lymphocyte Generation : + FOXP 3 + CD 25 + Role of STAT 3 in CD 4 (2007) (0)
- 319P A propensity score weighted study comparing two versus four-weekly pegylated liposomal doxorubicin regimen in metastatic breast cancer (2021) (0)
- 377 Oncogenic role of neuropilin-2 (2010) (0)
- Abstract OT1-04-07: VICTORIANE: A randomized phase 3 study assessing the addition of oral vinorelbine to aromatase inhibitors for the treatment of patients with metastatic breast cancer (2017) (0)
- HD204: Analytical biocomparability and clinical trial I progression of bevacizumab. (2019) (0)
- Mammography screening in France: Results of EDIFICE study. (2016) (0)
- Milestones over the development of SB3, a trastuzumab biosimilar. (2018) (0)
- Ki67 Assessment By qRT-PCR In OncotypeDx® Breast Recurrent Score®: Low Correlation With Immunohistochemistry Assessment of Ki67 And Prognostic Impact of Ki67 RNA Level of Expression. (2021) (0)
- Correction to: Biologic Drug Quality Assurance to Optimize HER2+ Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3 (2020) (0)
- A new agent in the family of antibody-drug conjugates. (2019) (0)
- A randomized phase I study comparing the pharmacokinetics of a bevacizumab (HD204) biosimilar to European Union- and United States of America-sourced bevacizumab (2021) (0)
- Prostate cancer screening: Rise and fall? (2013) (0)
- Cancer occurrence and cure: the power of the mind (2016) (0)
- A phase 2 randomized trial to evaluate the impact of a supervised exercise program on cardiotoxicity at 3 months in patients with HER2 overexpressing breast cancer undergoing adjuvant treatment by trastuzumab: design of the CARDAPAC study (2017) (0)
- First things first: Prevention, screening or care? (2016) (0)
- Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer (2019) (0)
- Prognosis value of a genetic score based on germline genetic variants in a prospective cohort of early triple-negative breast cancer patients. (2019) (0)
- Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes (2017) (0)
- 84PPresence of naturally occurring anti-telomerase CD4 Th1 immunity in glioblastoma (2017) (0)
- Impact of history of cancers among the close circle on cancer screening attendance. Results of the EDIFICE survey. (2006) (0)
- 5051 POSTER First-line Bevacizumab Plus Taxane-based Chemotherapy for Metastatic Breast Cancer (mBC) (2011) (0)
- Author Correction: Patterns of somatic structural variation in human cancer genomes (2020) (0)
- Individual screening of lung cancer in france: results of EDIFICE study: P1-194 (2007) (0)
- Fludarabine Versus No-Treatment In the Patients with CLL Stage A (2010) (0)
- Effect of neuropilin-2 expression on TGF-β1-epithelial-mesenchymal transition in colorectal cancer cells. (2011) (0)
- Assessment of quality and clinical similarity (pharmacokinetic and safety) of HD204, a biosimilar of bevacizumab. (2020) (0)
- [Perception of pT1a,b pN0 breast tumor prognosis by the French oncology community: Results of the EURISTIC national survey]. (2016) (0)
- 2064 POSTER Sequential taxane- and anthracycline-containing neoadjuvant regimens: the sequential order impact (2007) (0)
- [Follow-up in patients with early breast cancer]. (2011) (0)
- 1208 Being cured: What it means and what it takes (2015) (0)
- Pembrolizumab in the Treatment of Breast Cancer. (2022) (0)
- Anti-MUC1-C Antibody-Conjugated Nanoparticles Potentiate the Efficacy of Fractionated Radiation Therapy. (2020) (0)
- Author Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (0)
- Real-world patient-reported outcomes of women receiving initial endocrine-based therapy for HR+/HER2− advanced breast cancer in five European countries (2020) (0)
- 1320 Eribulin mesylate in metastatic breast cancer, a focus on safety and efficacy in elderly patients. Results from the EVHALAVEN multicentric retrospective cohort (2015) (0)
- Intraoperative intraperitoneal (IP) chemotherapy with cisplatin and escalated dose of epinephrine in patient with recurrent peritoneal carcinomatosis of ovarian cancer: A phase I study (2007) (0)
- Abstract B29: GP’s attitudes towards cancer screening: Does gender still matter? (2008) (0)
- 662 Neuropilin 2 expression on T CD4+ lymphocytes phenotypic study (2010) (0)
- Cancer risks, beliefs, and health care access among the underprivileged. (2013) (0)
- Cost-effectiveness analysis of routine use of eribulin in patients with metastatic breast cancer in France: A retrospective analysis. (2014) (0)
- Why the results of adjuvant pertuzumab in HER2-positive early breast cancer has been received as a mitigate success? (2017) (0)
- Can treatment with Cocculine improve the control of chemotherapy-induced emesis in early breast cancer patients? A randomized, multi-centered, double-blind, placebo-controlled Phase III trial (2012) (0)
- Final analysis of the phase 3 randomized clinical trial comparing HD201 vs. referent trastuzumab in patients with ERBB2-positive breast cancer treated in the neoadjuvant setting (2022) (0)
- Impact of BRCA status on outcomes and survival in high-risk early breast cancers. (2018) (0)
- Comprehensive evaluation of the pharmacokinetic profiles of SB3 and reference trastuzumab. (2018) (0)
- Interaction between STAT3 and immunosurveillance based on MICA. (2010) (0)
- Effect of ibandronate infusion duration (15 min versus 60 min) on renal function in breast cancer patients with bone metastases (2010) (0)
- 323PPATIENT SATISFACTION WITH SELF-ADMINISTRATION OF SUBCUTANEOUS (SC) TRASTUZUMAB VIA SINGLE-USE INJECTION DEVICE (SID) IN THE INTERNATIONAL, RANDOMISED PREFHER STUDY. (2014) (0)
- Abstract B33: Cancer survivors as messengers (2011) (0)
- Abstract P6-09-14: Awareness of brest cancer risk factors among lay persons and physicians (2016) (0)
- Knowledge of the French Population on Colorectal Cancer Screening: Data from the Edifice 3 Survey (2012) (0)
- PCN4 Overall Survival in Post-Menopausal Women with HR+/HER2- Advanced Breast Cancer Receiving a CDK 4 and 6 Inhibitor + Fulvestrant after Progressing on/after Prior Endocrine Therapy: A Fractional Polynomial Network Meta-Analysis (2020) (0)
- Sentinel lymph nodes before chemotherapy: The Besançon experience. (2013) (0)
- Prognostic F actors i n P rimary B reast S arcomas: A S eries o f Patients W ith L ong-Term F ollow-Up (2003) (0)
- 140 Prognostic factors of overall survival for patients with recurrent head and neck cancer: a retrospective study (2003) (0)
- Current or former smokers: Who wants to be screened? (2016) (0)
- Clinically Translatable Transcrocetin Delivery Platform for Correction of Tumor Hypoxia and Enhancement of Radiation Therapy Effects. (2023) (0)
- LEAF- 4L6715 enhances oxygenation in patients with acute respiratory distress syndrome (ARDS) due to severe COVID-19: Final results of a phase I/II clinical trial (2022) (0)
- SAT0412 Arthralgia Occurring under Aromatase Inhibitor Treatment for Breast Cancer. A Prospective Controlled Study. (2013) (0)
- Evolution of breast cancer screening in France from 2005 to 2008: results of the EDIFICE survey. (2009) (0)
- 3-year follow-up of a phase III study comparing SB3 (trastuzumab biosimilar) and reference trastuzumab in HER2 positive early or locally advanced breast cancer in neoadjuvant setting (2019) (0)
- Abstract PD13-11: PD13-11 Final Overall Survival Analysis of Monarch 2 : A Phase 3 trial of Abemaciclib Plus Fulvestrant in Patients with Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer (2023) (0)
- Abstract B03: Perceived causality of cancer and screening behaviors (2012) (0)
- [Pemetrexed development in oncology]. (2007) (0)
- Prognosis of pT1a,bN0 breast cancer: Perception from the French oncology community—Results from the EURISTIC survey. (2013) (0)
- [Biosimilars antibodies: positioning compared to originators - the experience in rheumatology and the biosimilars of trastuzumab in oncology]. (2019) (0)
- 3604 POSTER First-line Bevacizumab Plus Taxane-based Chemotherapy for Metastatic Breast Cancer (mBC): Cost Minimisation Analysis (2011) (0)
- Patient preference of trastuzumab administration (SC versus IV) in HER2-positive metastatic breast cancer: Results of the randomised Metaspher study (2016) (0)
- Author Correction: The evolutionary history of 2,658 cancers (2023) (0)
- Constitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohort (2017) (0)
- Abstract PD5-11: Association of immune gene expression with outcome in the MARIANNE phase 3 clinical trial in HER2-positive metastatic breast cancer (MBC) (2020) (0)
- 1100 Limiting factors to appropriate follow-up in cervical cancer screening (2015) (0)
- [Diffusion prophylactic axillary irradiation in breast cancer - Literature review]. (2021) (0)
- [Concomitant bifractionated radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in locally progressive, non-resectable epidermoid carcinomas of the pharynx: ten years experience at the Antoine Lacassagne center]. (2001) (0)
- Mammography utilization in women age 40 to 49: The French EDIFICE survey. (2010) (0)
- P1.01-010 Awareness of Lung Cancer Risk Factors among Lay Persons and Physicians: Topic: Tobacco, Radon, Air Pollution, Other Risk Factors (2017) (0)
- P3-16-08: A Phase 2, Randomized Open-Label Study of Iniparib, Administered Either Weekly or Twice-Weekly in Combination with Gemcitabine Plus Carboplatin in Patients with mTNBC. (2011) (0)
- Report of a young man with three successive curable cancers. (2008) (0)
- Effects of HER2 immuno-histochemistry expression levels on survival in patients treated by trastuzumab at the adjuvant setting in the SIGNAL/PHARE prospective cohort (2016) (0)
- Prostate cancer screening: contrasting trends (2015) (0)
- Abstract P2-13-04: Final survival analysis of a phase 3 study comparing SB3 (trastuzumab biosimilar) and reference trastuzumab in HER2-positive early or locally advanced breast cancer (2022) (0)
- 953 Early determination of cisplatin plasma concentration is an indicator of renal dysfunction (1995) (0)
- Abstract PD2-2: Final efficacy results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer (2015) (0)
- Abstract P2-09-10: Double heterozygosity for BRCA1 and BRCA2 pathogenic variants in a French metastatic breast cancer patient (2016) (0)
- 634 Uptake of mammography screening in women aged over 75 (2010) (0)
- 108 CEC and CTC in stage IV breast cancers treated with bevacizumab (Bv) and chemotherapy (CT) (2010) (0)
- Opinion on cancer screening: Impact on prescription and participation rates (2016) (0)
- Factors influencing colorectal cancer screening participation rates in 2016. (2017) (0)
- Establishing analytical and clinical similarity between HD201 and herceptin. (2020) (0)
- 5120 POSTER Is Extracapsular Tumour Spread a Prognostic Factor in Patients With Early Breast Cancer (2011) (0)
This paper list is powered by the following services:
Other Resources About Xavier Pivot
What Schools Are Affiliated With Xavier Pivot?
Xavier Pivot is affiliated with the following schools:
